Clinical trials of semaglutide in the SUSTAIN and STEP programs demonstrated average weight loss of 15% to 22% of baseline body weight over 68 weeks, with many participants achieving these results as monotherapy
When undergoing this therapy, your body will naturally begin to respond differently to diet and exercise
Manfredi Rizzo is former Director, Clinical Medical & Regulatory Department, Novo Nordisk Europe East and South and has given lectures, received honoraria and research support, and participated in conferences, advisory boards and clinical trials sponsored by pharmaceutical industry including Amgen, AstraZeneca, Boehringer Ingelheim, Kowa, Eli Lilly, Meda, Mylan, Merck Sharp & Dohme, Novo Nordisk, Novartis, Roche Diagnostics, Sanofi and Servier
Although there seemed to be more benefits, a large calorie restriction without increased physical activity was not an optimal strategy for physical fitness